Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 4/20 | 0.45 |
| ▸ | NMT2 | O60551 | 3/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31593295 | 0.90 | NMT1 (0.45) | NMT1NMT2FOLH1TLR2BACE1 | |
| SCHEMBL29474447 | 0.90 | FOLH1 (0.49) | NMT1NMT2FOLH1TLR2BACE1 | |
| SCHEMBL30734094 | 0.89 | FOLH1 (0.48) | NMT1NMT2FOLH1BACE1NOD1 | |
| SCHEMBL29777885 | 0.89 | FOLH1 (0.48) | NMT1NMT2FOLH1BACE1NOD1 | |
| SCHEMBL29960118 | 0.89 | FOLH1 (0.46) | FOLH1BACE1NOD1CPB2 | |
| SCHEMBL30376537 | 0.88 | ERAP2 (0.48) | NMT1NMT2FOLH1BACE1NOD1 | |
| SCHEMBL11697730 | 0.87 | NMT1 (0.48) | NMT1NMT2FOLH1TLR2BACE1 | |
| SCHEMBL29591503 | 0.87 | NMT1 (0.49) | NMT1NMT2FOLH1TLR2CPB2 | |
| SCHEMBL29777768 | 0.86 | FOLH1 (0.54) | FOLH1BACE1NOD1CPB2 | |
| SCHEMBL30578573 | 0.86 | FOLH1 (0.54) | FOLH1BACE1NOD1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220047698-A1 | SYNTHETIC INNATE IMMUNE RECEPTOR LIGANDS AND USES THEREOF | ALBERTA RES CHEMICALS INC (CA) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047698-A1 | SYNTHETIC INNATE IMMUNE RECEPTOR LIGANDS AND USES THEREOF | TLR3, TLR4, TLR9 | NMT1 1051/4885NMT2 1254/4885FOLH1 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.